Hypertension

The treatment cannot be granted full approval due to ongoing litigation.

Data from the CLICK trial presented at ASN Kidney Week 2021 suggests the use of chlorthalidone could reduce blood pressure by 11 mmHg among patients with stage 4 chronic kidney disease and poorly controlled hypertension.

Data show reduction in systolic BP was considered greater than safety concerns related to drugs and interventional treatment, and preference for no intervention over intervention.

Results of the 6-month follow-up from RADIANCE-HTN TRIO suggest the addition of antihypertensive medications following renal denervation could contribute to further blood pressure lowering in patients with treatment-resistant hypertension.

The adjusted change in 24-hour systolic blood pressure was -11.0 mm Hg in the chlorthalidone group and -0.5 mm Hg in the placebo group.

In patients with advanced heart failure, the median NT-proBNP AUC for valsartan was 1.19 compared to an AUC of 1.08 for sacubitril/valsartan.

The American College of Cardiology and American Heart Association guideline provides key highlights into the evaluation and diagnosis of adult patients with chest pain.

Data show nonfatal MI did not meet the threshold for surrogacy for all-cause mortality or CV mortality.

Gregory Weiss, MD, provides perspective on a recent scientific statement from the AHA outlining the role of health systems in promoting optimal adherence to hypertension therapies and helping patients achieve treatment goals.

In 1774 estimated discharges where a hospital region in the US had been indicated, 35.9% were diagnosed in the West and 32.3% in the South.

Women who delivered preterm had a greater than 1.6-fold risk of hypertension and women who delivered extremely preterm had a 2.2-fold risk within the next 10 years.

The letter pointed to a single deficiency related to an open inspection issue at a third-party facility.

New research suggests use of mobile technology could help improve blood pressure over a long-term period, with greater engagement with the technology associated with greater improvements in blood pressure.

An analysis of more than 4 million singleton deliveries from more than 2.1 million women provides insight into the apparent increase in risk associated with preterm delivery.

Data show the overall risk difference between the first and second doses of BNT162b2 was 1.76 per 100,000 persons.

In the primary endpoint, patients with severe HF had a 20% risk reduction compared to no significant treatment benefit in patients without severe HF.

Proposed new guidelines recommended against low-dose aspirin use for primary prevention of CVD in adults age 60 years or older, citing adverse effects.

A significantly increased risk of hospitalization from pneumonia was observed due to haemophilus influenzae.

Fever is present in both KD and MIS-C, but there is lower prevalence of the 5 KD defining clinical features in MIS-C.

Dr. Erickson discussed screening for children prone to sudden cardiac arrest and sudden cardiac death based on an updated AAP policy statement.

Differences in CV risk factors persisted between Black participants and White participants and may be due to social determinants of health.

Diabetes progression included greater likelihood of insulin treatment initiation, hyperglycemia, glycemic complications, and glucose-lowering prescriptions.

Data show SGLT2 inhibitor therapy, in comparison to GLP-1 RA therapy, was associated with slightly lower risk for myocardial infarction (MI) or stroke in patients with CVD.

An analysis of NHANES data presented at EASD 2021 suggests a return to a healthy weight in patients with obesity could result in reverse some of the cardiovascular risk associated with obesity, including high blood pressure and cholesterol disorders.

Data show the 20-year cumulative incidence of AVR was 3.4% in mild AS, 20.2% in moderate AS, and 54.6% in severe AS.

Research presented at the AHA's Hypertension Scientific Sessions details the increased prevalence of cardiac autonomic neuropathy and decreased survival probability associated with a non-dipping blood pressure at night.

In patients with T2D without prior CVD, chronic kidney disease was the single risk factor associated with highest risk of MACE.

The American Heart Association has released a scientific statement outlining the current knowledge base surrounding potential prevention and treatment strategies for the management of obesity hypertension.

No significant difference in mortality or stroke at 30 days or 1 year was seen in patients who underwent TAVR for bicuspid or tricuspid aortic stenosis.

A total of 269 participants were considered potentially overtreated, while 109 participants were appropriately on target, and 56 participants potentially undertreated.